Outcome of Board Meeting

August 03, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra-Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai 400 051 Scrip Code: 544184 Trading Symbol: BOROSCI Dear Sirs, Sub: Outcome of the Board Meeting In furtherance of our intimation dated July 27, 2026, we hereby inform you that the Board of Directors of the Company at its meeting held today, i.e. August 03, 2026, has, inter alia, considered and approved the following: (a) Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026. The aforesaid Financial Results along with Limited Review Reports of the Statutory Auditor are attached and are also made available on the Company’s website at Financial Results - Borosil Scientific. (b) Modifications / amendments to the Company’s ESOP schemes viz. (i) Borosil Scientific Limited – Special Purpose Employee Stock Option Plan 2023 (“SP-ESOP 2023”) and (ii) Borosil Scientific Limited – Employee Stock Option Scheme (“BSL ESOS”), in accordance with the provisions of the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 and the Companies Act, 2013, based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the Members of the Company and other regulatory / statutory approvals as may be necessary. The aforesaid ESOP schemes are being amended mainly for following purposes: • To arrange shares for Employee Stock Option (“Options”) holders upon exercise of Options, either from primary issuance or secondary acquisition through Trust route. Currently, the Company directly allots shares to Options holders by way of primary issuance. (for both Schemes). • To increase the maximum limit of discount percentage for grant of new Options from existing 10% to 20% to the closing market price of shares one day prior to the date of grant of options (for BSL ESOS). The meeting of the Board of Directors commenced at 3:10 p.m. (IST) and concluded at 4:15 p.m. (IST). Yours faithfully, For Borosil Scientific Limited Ramavtar Sharma Company Secretary & Compliance Officer CHATURVEDI (I SHAH Chartered Accountants Independent Auditor's Review Report on Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 The Board of Directors of Borosil Scientific Limited 1 . We have reviewed the accompanying statement of unaudited standalone financial results of Borosil Scientific Limited ("the Company") for the quarter 30th June 2026 ("the statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulation"), as amended. 2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review. 3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making enquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we don't express an audit 9pinion. Head Office: 912, Tulsiani Chambers, 212, Nariman Point, Mumbai-400 021, India. Tel.: +91224163 8500 • Fax: +91224163 8595 URL: www.cas.ind.in CHATURVEDI (I SHAHLLP Chartered Accountants 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in • which it is to be disclosed, or that it contains any material misstatement. For Chaturvedi & Shah LLP Chartered Accountants Registration No. 1Q J 720W/W100355 Anuj Bhatia Partner Membership No. 122179 UDIN No: 26122179PYJPZX1805 Place: Mumbai Date: 03rd August, 2026 Continuation sheet.. BOROSlt: BOROSIL SCIENTIFIC LIMITED S ci e nt i fi c CIN: L74999MH1991PLC061851 Regd. Office: 1101, 11th floor, Crescenzo, G-Block, Plot No.C-38, Opp. MCA Club, Bandra Kurla Complex, Bandra (East), Mumbai 400 051 Tel.No.(022) 67406300 Fax No.(022) 67406514 Website : www.borosilscientific.com Email : bsl@borosil.com UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026 (Rs. in lakhs except as stated) Standalone s. Particulars Quarter ended Year ended No. (30/06/2026) (31/03/2026) (30/06/2025) (31/03/2026) I. Income: Revenue From Operations 9,989.68 13,191.95 8,900.95 42,753.08 Other Income 279.62 212.27 306.04 1,018.42 Total Income (I) 10,269.30 13,404.22 9,206.99 43,771.50 II. Expenses: Cost of Materials Consumed 3,896.58 4,174.47 3,065.53 14,486.60 Purchases of Stock-in-Trade 39.17 250.64 148.70 596.29 Changes in Inventories of Work-in-progress, Finished (869.06) 216.26 (125.12) (145.70) Goods and Stock-in-trade Employee Benefits Expense 1,795.05 1,557.64 1,565.30 6,453.05 Finance Costs 10.45 5.81 18.19 42.12 Depreciation and Amortization Expense 444.91 431.62 446.68 1,752.11 Other Expenses 4,021.09 3,883.01 3,360.15 14,359.63 Total Expenses (II) 9,338.19 10,519.45 8,479.43 37,544.10 Ill. Profit Before Exceptional Items and Tax (I -II) 931.11 2,884.77 727.56 6,227.40 IV. Exceptional Items (Refer Note 2) - - 661.31 852.82 V. Profit Before Tax (Ill -IV) 931.11 2,884.77 66.25 5,374.58 VI. Tax Expense: (1) Current Tax 175.48 738.08 - 1,441.35 (2) Deferred Tax 71.28 (6.88) 20.49 (39.23) Total Tax Expenses 246.76 731.20 20.49 1,402.12 VII. Profit for the Period / Year (V -VI) 684.35 2,153.57 45.76 3,972.46 VIII. Other Comprehensive Income (OCI) Items that will not be reclassified to profit or loss: a) Re-measurement gains / (losses) on defined benefit (8.41) (73.58) 2.47 (61.35) plans b) Income tax effect on above 2.12 18.52 (0.62) 15.44 Total Other Comprehensive Income (6.29) (55.06) 1.85 (45.91) IX. Total Comprehensive Income for the Period/ Year (VII 678.06 2,098.51 47.61 3,926.55 + VIII) X. Paid-up Equity Share Capital (Face value of Re. 1/- 889.47 889.47 889.46 889.47 each fully paid up) XI. Other Equity excluding Revaluation Reserve 44,190.79 XII. Earning per equity share (in Rs.) (Face value of Re. 1/- each) Basic (Not Annualised)* 0.77* 2.42 * 0.05 * 4.47 Diluted (Not Annualised)* 0.77* 2.42 * 0.05 * 4.47 BOROSIL SCIENTIFIC LIMITED UNAUDITED STANDALONE SEGMENT INFORMATION FOR THE QUARTER ENDED 30TH JUNE, 2026 (Rs. in lakhs) Standalone s. Particulars Quarter ended Year ended No. (30/06/2026) (31/03/2026) (30/06/2025) (31/03/2026) 1 Segment Revenue : a. Scientific - Laboratory Glass & equipment and 5,982.56 9,844.79 5,625.81 29,15 [Showing first 8,000 characters — download PDF for full document]